David E. Uehling

$329,520.45asInterim Scientific Director, Therapeutic Innovation and Drug Discovery

Employed by Ontario Institute For Cancer Research in 2025, according to Government of Ontario public salary records.

Position

Interim Scientific Director, Therapeutic Innovation and Drug Discovery

Employer

Ontario Institute For Cancer Research

Salary Information

Historical salary and taxable benefits from 2009 to 2025.

YearPositionSalaryBenefitsPerformance
2025
Interim Scientific Director, Therapeutic Innovation and Drug Discovery
$329,520.45
$1,477.44
10.4%
2024
Director, Medicinal Chemistry
$298,484.91
$1,477.44
11.95%
2023
Director, Medicinal Chemistry
$266,626.40
$1,462.86
6.1%
2021
Director, Medicinal Chemistry
$251,290.86
$1,244.16
12.32%
2019
Scientific Advisor
$223,721.05
$1,092.78
2.86%
2018
Scientific Advisor
$217,502.05
$1,062.30
2.23%
2017
Scientific Advisor and Group Leader
$212,765.10
$1,039.20
10.2%
2011
Chemist
$193,067.42
$781.41
0.11%
2010
Chemist
$192,847.20
$844.23
7.75%
2009
Chemist
$209,038.08
$714.62

The Ontario Sunshine List reports that David E. Uehling was paid $329,520.45 in 2025 as Interim Scientific Director, Therapeutic Innovation and Drug Discovery at Ontario Institute For Cancer Research. This represents a 10.4% increase over the previous year's reported salary. David E. Uehling has appeared on the Ontario Sunshine List 10 times between 2009 and 2025, with reported earnings peaking at $329,520.45 in 2025. In addition to salary, $1,477.44 in taxable benefits was disclosed for 2025. Ontario Institute For Cancer Research reports under the Other Public Sector Employers sector of Ontario's public sector salary disclosure.

Top earning Interim Scientific Director, Therapeutic Innovation and Drug Discoverys in Ontario Institute For Cancer Research

NameSalary
David E. Uehling$329,520.45
NameSalary
Leslie Radvanyi
President and Scientific Director
$539,745.00
Christine Williams
Acting President and Head, Implementation Science
$395,996.12
Lincoln Stein
Acting Scientific Director and Head, Adaptive Oncology
$383,286.80
Jared T. Simpson
Interim Scientific Director and Principal Investigator
$331,897.15
Peter Goodhand
Executive Lead
$321,484.80
Jeanette Dias D'Souza
Senior Vice President, Group Chief Financial Officer
$319,995.00
Robert V. Campos
Senior Director
$256,531.19
Rebecca L. Tamarchak
Head, Strategy, Governance and Partnerships
$249,995.20
David M Sutton
Senior Director
$240,445.77